Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI with or without statins for refractory generalized chronic graft-versus-host disease
ChiCTR1900026602Phase 4Recruiting
- Sponsor
- Medical Center of Hematology, Xinqiao Hospital, Army Medical University
- Start
- Oct 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imatinib, dasatinib and atorvastatin in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Medical Center of Hematology, Xinqiao Hospital, Army Medical University. Primary endpoints: Severity score of chronic graft-versus-host disease, Target organ types of chronic graft-versus-host disease and 5 more. Started Oct 2019; status: recruiting.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ChiCTR1900026602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026602.